Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points

ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data, presented at EADV in September, further support and derisk the program

Read more at globenewswire.com